Yunnan Energy International Valuation

Is T43 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of T43 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: T43 (SGD0.08) is trading below our estimate of fair value (SGD0.5)

Significantly Below Fair Value: T43 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for T43?

Key metric: As T43 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for T43. This is calculated by dividing T43's market cap by their current revenue.
What is T43's PS Ratio?
PS Ratio	0.5x
Sales	HK$453.89m
Market Cap	HK$217.60m

T43 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.7x
Enterprise Value/EBITDA	4892.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does T43's PS Ratio compare to its peers?

The above table shows the PS ratio for T43 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.9x
BKZ Suntar Eco-City	1.5x	n/a	S$7.9m
UUK Pasture Holdings	0.3x	n/a	S$6.3m
5WA OUE Healthcare	0.8x	n/a	S$120.0m
EHG Econ Healthcare (Asia)	0.9x	n/a	S$57.2m
T43 Yunnan Energy International	0.5x	n/a	S$217.6m

Price-To-Sales vs Peers: T43 is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.9x).

Price to Sales Ratio vs Industry

How does T43's PS Ratio compare vs other companies in the SG Healthcare Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
1H3 Clearbridge Health	0.2x	n/a	US$1.84m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: T43 is good value based on its Price-To-Sales Ratio (0.5x) compared to the SG Healthcare industry average (1.5x).

Price to Sales Ratio vs Fair Ratio

What is T43's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

T43 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate T43's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IHH Healthcare Berhad

RM 63.4b

An investment holding company, provides healthcare services in Malaysia, Singapore, Turkey, India, China, Japan, Turkey, Europe, and internationally.

Q0F

RM 2.19

-0.9%

27.3%

Econ Healthcare (Asia)

S$57.2m

An investment holding company, engages in the operation of medicare centers and nursing homes for eldercare in Singapore, Malaysia, and China.

EHG

S$0.21

7.5%

2.4%

Quantum Healthcare

S$16.0m

Engages in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases in Singapore.

V8Y

S$0.002

-33.3%